Investigational drug · Phase 3
Filgotinib
Also called: GS-6034, GLPG0634
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
4 still active
All registered trials
61
Any phase or sponsor naming "Filgotinib"
First trial start
2017
Feb 23, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Filgotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Polyarticular Course Juvenile Idiopathic Arthritis
- Juvenile Idiopathic Arthritis (JIA)
- Axial Spondyloarthritis
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Ulcerative colitis · Ankylosing spondylitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Filgotinib" as an intervention, largest first.
PfizerPfizer (PFE)
NCT07177209 · 4,000 participants · Start Apr 1, 2026 · Primary completion Oct 30, 2026
Drug: Non-Interventional Study · For: Ulcerative Colitis
Sites: Tadworth, United Kingdom
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisPivotal-lookingCompleted
Alfasigma S.p.A.Industry
NCT03025308 · 2,731 participants · Start Feb 28, 2017 · Primary completion May 16, 2025
Drug: Filgotinib; Placebo to match filgotinib · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Gilbert, Arizona; Phoenix, Arizona · 345 sites in all
- Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexatePivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02889796 · 1,759 participants · Start Aug 30, 2016 · Primary completion Jul 4, 2018
Drug: Filgotinib; Placebo to match filgotinib and 3 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 230 sites in all
- Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseasePivotal-lookingCompleted
Lakefront Biotherapeutics NVIndustry
NCT02914561 · 1,372 participants · Start Oct 31, 2016 · Primary completion Nov 11, 2022
Drug: Filgotinib · For: Crohn's Disease
Sites: Dothan, Alabama; Sun City, Arizona; Coronado, California · 513 sites in all
- Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02914522 · 1,351 participants · Start Nov 14, 2016 · Primary completion Mar 31, 2020
Drug: Filgotinib; PTM filgotinib · For: Ulcerative Colitis
Sites: Dothan, Alabama; Scottsdale, Arizona; Long Beach, California · 343 sites in all
- Prospective Observational Study of Filgotinib in Subjects With Rheumatoid ArthritisActive, not recruiting
Alfasigma S.p.A.Industry
NCT04871919 · 1,304 participants · Start May 11, 2021 · Primary completion Jun 2028
Drug: Filgotinib · For: Rheumatoid Arthritis
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 89 sites in all
- Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02886728 · 1,252 participants · Start Aug 8, 2016 · Primary completion Oct 5, 2018
Drug: Filgotinib; Placebo to match filgotinib and 2 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 186 sites in all
- Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseasePivotal-lookingTerminated
Lakefront Biotherapeutics NVIndustry
NCT02914600 · 1,188 participants · Start Mar 17, 2017 · Primary completion Aug 1, 2023
Drug: Filgotinib; Placebo · For: Crohn's Disease
Sites: Dothan, Alabama; Sun City, Arizona; Coronado, California · 486 sites in all
- Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisPivotal-lookingCompleted
Alfasigma S.p.A.Industry
NCT02914535 · 1,173 participants · Start Feb 23, 2017 · Primary completion Sep 8, 2026
Drug: Filgotinib; Placebo · For: Ulcerative Colitis
Sites: Dothan, Alabama; Scottsdale, Arizona; Long Beach, California · 323 sites in all
Lakefront Biotherapeutics NVIndustry
NCT02065700 · 739 participants · Start Feb 25, 2014 · Primary completion Jan 19, 2023
Drug: Filgotinib · For: Rheumatoid Arthritis
Sites: Gilbert, Arizona; Mesa, Arizona; Hemet, California · 111 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Computational analysis of KLF6/PDE4B-associated ferro-aging signatures and candidate drugs in benign prostatic hyperplasia.
Liu T, Chen X, Zheng J · Biochem Biophys Res Commun 2026
- Effectiveness and Safety of Janus Kinase Inhibitors in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Real-world Studies.
Huang J, Wu Y, Zhang C, et al. · Digestion 2026
- Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort.
Etani Y, Okita Y, Tsujimoto K, et al. · Rheumatology (Oxford) 2026
- Temporal Trends in Janus Kinase Inhibitor (JAKi) Use Across Five European Countries: A DARWIN EU Network Study.
Chen X, Barbulescu A, Corby G, et al. · Pharmacoepidemiol Drug Saf 2026
- Filgotinib effective across the axSpA spectrum in phase III trial.
Onuora S · Nat Rev Rheumatol 2026
- Development and Validation of a Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Method for the Determination of Alpelisib, a Novel Phosphatidylinositol 3-Kinase Inhibitor, and Its Application to a Pharmacokinetic Study in Mice.
Dixit A, Das A · Drug Res (Stuttg) 2026
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- ABX464ObefazimodPhase 35 trials
Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.